Drug Trial Radar · NCT05967117
Chest CT Using Low-concentration Iodine Contrast Media
Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
370
Planned (sponsor's estimate)
Start
Nov 24, 2023
Primary completion
Nov 2024
Study completion Nov 2024
Sponsor
- Lead sponsor
- Jung Im JungAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Taejoon Pharmaceutical Co., Ltd.
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the quality of images when low-concentration iodine contrast agents is used in chest CT with low tube voltage and if they can be used in routine imaging. The primary endpoint of the study was the quality of the image and comparison of chest CT by using low and conventional concentration iodine contrast agents with low tube voltage and chest CT by using the conventional concentration iodine contrast agents with the conventional tube voltage; The secondary endpoint is optimizing chest CT protocol using an iodine contrast agent.
Conditions
- Pulmonary Disease
Interventions
Iohexol (320mgI/mL) with 120kVpDrug
Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Iohexol (320mgI/mL) with 100kVpDrug
Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Iohexol (270mgI/mL) with 100kVpDrug
Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Iohexol (240mgI/mL) with 100kVpDrug
Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anatomic depiction (including image sharpness)Time frame: 12 months after the CT scan (Chest contrast-enhanced CT is a 1-day procedure, but evaluating all the images will be done one year after the 1st CT scan.)
- NoiseTime frame: 12 months after the CT scan
- Contrast-related artifactTime frame: 12 months after the CT scan
- Overall diagnostic acceptabilityTime frame: 12 months after the CT scan
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Chonnam National University Hospital
Gwangju, South Korea · Completed
Seoul National University Hospital
Seoul, South Korea · Completed
Bucheon St. Mary's Hospital, The Catholic University of Korea
Bucheon-si, Gyeonggi-do, South Korea · Completed
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea · Recruiting
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea · Recruiting
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, Seocho-gu, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.